|
Dr. Carlsson is a scientific advisor to Cortex’s Board of Directors and was the co-recipient of the 2000 Nobel Prize for Medicine. Dr. Carlsson is also currently CEO of Carlsson Research, a development stage neuroscience company that grew out of his research in the Department of Pharmacology at the University of Göteborg, Sweden. Dr. Carlsson is Professor Emeritus at the University of Göteborg and is a member of the Swedish Academy of Sciences and a foreign affiliate of the U.S. National Academy of Sciences. Dr. Carlsson’s research has revolutionized the understanding of a number of psychiatric and neurological disorders, including Parkinson’s disease, schizophrenia, and depression, which has led to the development of new pharmaceutical treatments. Dr. Carlsson’s research achievements include the discovery of dopamine as a major neurotransmitter in the brain, as well as dopamine’s importance in Parkinson’s disease and schizophrenia. Dr. Carlsson received a M.D. and Ph.D. in Pharmacology from the University of Lund, Sweden and was immediately appointed Assistant Professor of Pharmacology. He was promoted to Associate Professor in 1956, and was an early pioneer in the pharmacology of calcium regulation, an area of research that later led others to the development of calcium channel blockers commonly used today to regulate cardiac function.
| 